文献速递心脑血管急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

索格列净用于糖尿病合并近期心衰恶化患者

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
PubMed 文献 · N Engl J Med · 2020-11-16
一句话结论糖尿病合并近期心衰恶化患者,出院前或出院后短期启用索格列净可显著减少心血管死亡与心衰住院/急诊就诊总事件。

SOLOIST-WHF为多中心双盲RCT,纳入1222例因心衰恶化近期住院的2型糖尿病患者,随机接受索格列净或安慰剂,中位随访9.0个月;48.8%出院前首剂、51.2%出院后中位2天首剂。主要终点(心血管死亡与心衰住院/紧急就诊首次及后续事件总数)发生率索格列净组51.0 vs 安慰剂组76.3事件/100患者年(HR 0.67,95%CI 0.52–0.85,P<0.001)。心血管死亡与全因死亡无显著差异;腹泻与严重低血糖更常见。

要点

  • 因心衰恶化住院的2型糖尿病患者,出院前或出院后短期启用索格列净,主要终点事件率51.0 vs 76.3/100患者年(HR 0.67,95%CI 0.52–0.85,P<0.001)。
  • 心血管死亡率索格列净组10.6 vs 安慰剂组12.5/100患者年(HR 0.84,95%CI 0.58–1.22),全因死亡13.5 vs 16.3(HR 0.82,95%CI 0.59–1.14),均无显著差异。
  • 腹泻更常见(6.1% vs 3.4%),严重低血糖更常见(1.5% vs 0.3%),需在启用时关注。
  • 低血压(6.0% vs 4.6%)与急性肾损伤(4.1% vs 4.4%)发生率与安慰剂相似。
  • 按首剂时机分层的预设亚组中获益一致,支持出院前或出院后短期启动。

适用人群与场景

  • 因心衰恶化近期住院的2型糖尿病患者,随机化后中位随访9.0个月。
  • 首剂在出院前给予者占48.8%,出院后给予者占51.2%(中位出院后2天)。
  • 原文未提及具体纳入/排除标准及急诊/院前场景。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 索格列净组于出院前或出院后短期(出院后中位2天)启动首剂,具体剂量、途径、频次原文未提及。

红旗征与不能漏的情况

  • 腹泻:索格列净组6.1% vs 安慰剂组3.4%。
  • 严重低血糖:索格列净组1.5% vs 安慰剂组0.3%。
  • 低血压:索格列净组6.0% vs 安慰剂组4.6%。
  • 急性肾损伤:索格列净组4.1% vs 安慰剂组4.4%。

研究设计与关键结果

  • 多中心、双盲RCT,1222例因心衰恶化近期住院的2型糖尿病患者随机(索格列净608例、安慰剂614例),中位随访9.0个月;因赞助方资金中断提前终止。
  • 主要终点为心血管死亡与心衰住院/紧急就诊的首次及后续事件总数;共600起事件(索格列净245、安慰剂355),事件率51.0 vs 76.3/100患者年(HR 0.67,95%CI 0.52–0.85,P<0.001)。
  • 心血管死亡事件率10.6 vs 12.5/100患者年(HR 0.84,95%CI 0.58–1.22);全因死亡13.5 vs 16.3/100患者年(HR 0.82,95%CI 0.59–1.14)。
  • 不良事件:腹泻6.1% vs 3.4%,严重低血糖1.5% vs 0.3%,低血压6.0% vs 4.6%,急性肾损伤4.1% vs 4.4%。
  • 按首剂时机分层的预设亚组中获益一致。

证据类型、等级与局限

  • 证据类型:多中心、双盲、随机对照试验(RCT)。
  • 局限:因赞助方资金中断提前终止;心血管死亡与全因死亡无显著差异;原文未提及证据等级或推荐强度。

对床旁实践的改变

  • 对因心衰恶化住院的2型糖尿病患者,可考虑在出院前或出院后短期启用索格列净,以降低心血管死亡与心衰住院/紧急就诊总事件。
  • 启用时需关注腹泻与严重低血糖风险;低血压与急性肾损伤发生率与安慰剂相似。
  • 原文未提及具体剂量方案,不能将研究方案剂量外推为通用推荐。

指南或共识出处

  • SOLOIST-WHF(ClinicalTrials.gov NCT03521934),由Sanofi与Lexicon Pharmaceuticals资助,发表于N Engl J Med。

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure or death from cardiovascular causes among patients with stable heart failure. However, the safety and efficacy of SGLT2 inhibitors when initiated soon after an episode of decompensated heart failure are unknown.

METHODS: We performed a multicenter, double-blind trial in which patients with type 2 diabetes mellitus who were recently hospitalized for worsening heart failure were randomly assigned to receive sotagliflozin or placebo. The primary end point was the total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure (first and subsequent events). The trial ended early because of loss of funding from the sponsor.

RESULTS: A total of 1222 patients underwent randomization (608 to the sotagliflozin group and 614 to the placebo group) and were followed for a median of 9.0 months; the first dose of sotagliflozin or placebo was administered before discharge in 48.8% and a median of 2 days after discharge in 51.2%. Among these patients, 600 primary end-point events occurred (245 in the sotagliflozin group and 355 in the placebo group). The rate (the number of events per 100 patient-years) of primary end-point events was lower in the sotagliflozin group than in the placebo group (51.0 vs. 76.3; hazard ratio, 0.67; 95% confidence interval [CI], 0.52 to 0.85; P<0.001). The rate of death from cardiovascular causes was 10.6 in the sotagliflozin group and 12.5 in the placebo group (hazard ratio, 0.84; 95% CI, 0.58 to 1.22); the rate of death from any cause was 13.5 in the sotagliflozin group and 16.3 in the placebo group (hazard ratio, 0.82; 95% CI, 0.59 to 1.14). Diarrhea was more common with sotagliflozin than with placebo (6.1% vs. 3.4%), as was severe hypoglycemia (1.5% vs. 0.3%). The percentage of patients with hypotension was similar in the sotagliflozin group and the placebo group (6.0% and 4.6%, respectively), as was the percentage with acute kidney injury (4.1% and 4.4%, respectively). The benefits of sotagliflozin were consistent in the prespecified subgroups of patients stratified according to the timing of the first dose.

CONCLUSIONS: In patients with diabetes and recent worsening heart failure, sotagliflozin therapy, initiated before or shortly after discharge, resulted in a significantly lower total number of deaths from cardiovascular causes and hospitalizations and urgent visits for heart failure than placebo. (Funded by Sanofi and Lexicon Pharmaceuticals; SOLOIST-WHF ClinicalTrials.gov number, NCT03521934.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020. PMID: 33200892. doi:10.1056/NEJMoa2030183

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。